Monday, November 8, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1358
Clusters of Psoriatic Arthritis Patients at Baseline Based on Different Ultrasound Detected Synovitis: Exploratory Analysis from a Phase III Study
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1076
Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
Health Services Research Poster II: Care Models and Innovation (1061–1082)- 8:30AM-10:30AM
-
Abstract Number: 1102
Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1346
Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis: Results from Phase 3 Trials Through 1 Year
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1061
Comparing Consultation Patterns Across Telehealth Platforms and Face-to-Face Clinic in the Military Health System
Health Services Research Poster II: Care Models and Innovation (1061–1082)- 8:30AM-10:30AM
-
Abstract Number: 1109
Comparison of Diagnostic Criteria in Behçet’s Disease and Sensitivity in Diagnosing Severe Manifestations
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1241
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)- 8:30AM-10:30AM
-
Abstract Number: 1370
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)- 8:30AM-10:30AM
-
Abstract Number: 1208
Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)- 8:30AM-10:30AM
-
Abstract Number: 1045
Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)- 8:30AM-10:30AM
-
Abstract Number: 1231
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)- 8:30AM-10:30AM
-
Abstract Number: 1090
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1129
Cost-effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Advanced Knee Osteoarthritis and Class III Obesity
Osteoarthritis – Clinical Poster III (1118–1134)- 8:30AM-10:30AM
-
Abstract Number: 1085
COVID 19 Infection in Patients with Rheumatic Immune-mediated Diseases in a Single University Hospital: Matched Case-control Study